Management of arrhythmias

Clinics in Geriatric Medicine

Volumn 16, Issue 3, 2000, Pages 593-618

  Lampert, Rachel ^b   Ezekowitz, Michael D ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; WARFARIN; XAMOTEROL; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

AGED; ANTICOAGULATION; BRADYCARDIA; CONGESTIVE HEART FAILURE; DRUG CONTRAINDICATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART PACING; HUMAN; PROGNOSIS; REVIEW; AGE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; DEFIBRILLATOR; HEART VENTRICLE TACHYCARDIA; INCIDENCE; PREVALENCE; RISK FACTOR;

AGE FACTORS; AGED; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; PREVALENCE; PROGNOSIS; RISK FACTORS; TACHYCARDIA, VENTRICULAR;

EID: 0033624144     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(05)70030-6     Document Type: Article

References (183)

1. ACC/AHA Task Force on Practice Guidelines: ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices
2. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias
3. Effects of permanent pacemaker and oral theophylline in sick sinus syndrome
4. Comparison of the safety and efficacy of flecainide versus propafeneone in hospital outpatients with symptomatic paroxysmal atrial fibrillation/flutter
5. Circus movement in rabbit atrial muscle as a mechanism of tachycardia
6. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials
7. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome
8. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome
9. The Cardiac Insufficiency Bisoprolol Study II: A randomised trial
10. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure
11. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter
12. Effect of Propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients >62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction >40%
13. Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients
14. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation
15. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure
16. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases
17. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results
18. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results
19. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation
20. Independent risk factors for atrial fibrillation in a population-based cohort
21. Impact of atrial fibrillation on the risk of death
22. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction
23. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation
24. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation
25. Effects of aging on asynchronous left ventricular regional function and global ventricular filling in normal human subjects
26. Oral loading with propafenone
27. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation
28. Permanent pacemaker treatment in older age groups
29. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation
30. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance
31. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation
32. A randomized study of the prevention of sudden death in patients with coronary artery disease
33. Nonsustained ventricular tachycardia in patients with coronary artery disease: Role of electrophysiologic study
34. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
35. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS registry)
36. Atrial premature beats coupling interval determines lone paroxysmal atrial fibrillation onset
37. Cardioversion of atrial fibrillation in the elderly
38. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the flecainide and propafenone Italian study investigators
39. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter
40. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required?
41. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation
42. A comparison of enalapril with hyralazine-isosorbide dinitrated in the treatment of chronic congestive heart failure
43. Dual-chamber versus ventricular pacing
44. Canadian atrial fibrillation anticoagulation (cafa) study
45. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion
46. Effects of age on intrinsic heart rate, heart rate variability, and AV conduction in healthy humans
47. Long- and short-term risk of sudden coronary death
48. Atrial fibrillation
49. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation
50. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin
51. Intravenous digoxin in acute atrial fibrillation
52. Managing chronic atrial fibrillation: A markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone
53. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation
54. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias
55. Randomised trial of low-dose amiodarone in severe congestive heart failure
56. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials
57. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The cardiac arrhythmia suppression trial
58. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation
59. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: A multicenter study
60. Radiofrequency catheter ablation in the treatment of supraventricular tachycardia in the elderly
61. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke
62. Preventing stroke in patients with atrial fibrillation
63. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: The Veterans Affairs Cooperative Study
64. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation
65. Proarrhythmia in patients treated for atrial fibrillation or flutter
66. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm
67. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens
68. Prevalence, age distribution, and gender of patients with atrial fibrillation
69. Meeting highlights 47th annual scientific sessions of the american college of cardiology
70. Quality of life and outcomes after radiofrequency his-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation
71. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
72. Long-term prognostic significance of ambulatory electrocardiographic findings in apparently healthy subjects >60 years of age
73. Atrial pacing periablation for prevention of paroxysmal atrial fibrillation
74. Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: A randomized study
75. Intravenous diltiazem for the treatment of patients with arial fibrillation or flutter and moderate to severe congestive heart failure
76. Mechanism of death in heart failure
77. Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulation therapy
78. Programmed electrical stimulation in patients with high-grade ventricular ectopy: Electrophysiologic findings and prognosis for survival
79. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter
80. Long-term effect of cardioversion on peak oxygen consumption in chronic atrial fibrillation
81. Functional capacity before and after cardioversion of atrial fibrillation: A controlled study
82. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins
83. Effect of propranolol in reducing mortality in older myocardial infarction patients
84. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure
85. Age and gender influences on rate and duration of paroxysmal atrial fibrillation
86. Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillation
87. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine
88. Survival after cardiac arrest outside hospital in Sweden
89. An analysis of the lowest dose of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
90. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo
91. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
92. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation
93. Accuracy of laboratory and portable monitor international normalized ratio determinations
94. Epidemiologic features of chronic atrial fibrillation
95. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation
96. Atrial fibrillation is an independent determinant of low cognitive function
97. Use of electrophysiologic testing in patients with nonsustained ventricular tachycardia: Prognostic and therapeutic implications
98. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: Results of a randomized, controlled study
99. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: Randomized crossover study
100. Left atrial contribution to ventricular filling during the course of evolving heart failure
101. Lone atrial fibrillation in elderly persons
102. The natural history of lone atrial fibrillation
103. Premature ventricular complexes in the absence of identifiable heart disease
104. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation
105. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing
106. Permanent pacemaker selection and subsequent survival in elderly medicare pacemaker recipients
107. Atrial fibrillation in elderly patients: Prevalence and comorbidity in general practice
108. Xamoterol improves the control of chronic atrial fibrillation in elderly patients
109. Amiodarone and torsades de pointes
110. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure
111. Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation
112. Characterization of different subsets of atrial fibrillation in general practice in France
113. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil
114. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure
115. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital
116. Impaired left atrial mechanical function after cardioversion: Relation to the duration of atrial fibrillation
117. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5-year study
118. Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: The cardiovascular health study
119. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor
120. The natural course of untreated sick sinus syndrome and identification of the variables predictive of unfavorable outcome
121. Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation
122. Prognostic significance of atrial fibrillation in advanced heart failure
123. Syncope in advanced heart failure: High risk of sudden death regardless of origin of syncope
124. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis
125. Long-term follow-up after radiofrequency modification of the atrioventricular node in patients with atrial fibrillation
126. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
127. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation
128. Consistency of treatment effects in the Multicenter Unsustained Tachycardia Trial
129. Atrial fibrillation follow-up investigation of rhythm management - The affirm study design
130. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
131. Atrial fibrillation and stroke prevention in the community
132. Atrial fibrillation and dementia in a population-based study
133. Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction
134. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
135. Efficacy of the implantable cardioverter-defibrillator in the elderly
136. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen Afasak Study
137. Management of patients with atrial fibrillation: A statement for health care professionals
138. Incidence of and risk factors for atrial fibrillation in older adults
139. What is meant by a 'controlled' ventricular rate in atrial fibrillation?
140. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin
141. Risk factors for the development of recurrent atrial fibrillation: Role of pacing and clinical variables
142. Risks and benefits of antiarrhythmic therapy
143. Long-term pacing in sinus node disease: Effects of stimulation mode on cardiovascular morbidity and mortality
144. Long-term follow-up of patients after transcatheter direct current ablation of the atrioventricular junction
145. Clinical spectrum of the sick sinus syndrome
146. Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing
147. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter
148. Beta-blockade in heart failure
149. Long-term follow-up of patients with sick sinus syndrome: A comparison of clinical aspects among unpaced, ventricular inhibited paced, and physilogically paced groups
150. Cost-effectiveness of transesphogeal echocardiographic-guided cardioversion: A decision analytic model for patients admitted to the hospital with atrial fibrillation
151. The role of pacing modality in determining long-term survival in the sick sinus syndrome
152. Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm
153. Survival in sinoatrial disorder (sick-sinus syndrome)
154. Survival and functional independence after implantation of permanent pacemaker in octogenarians and nonagenarians
155. Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation
156. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies
157. Symptomatic bradyarrhythmias in the adult: Natural history following ventricular pacemaker implantation
158. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy
159. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia
160. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation
161. Improving survival for patients with atrial fibrillation and advanced heart failure
162. Adjusted-dose warfarin versus low intensity, fixed dose, warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomized clinical trials
163. Design of a multicenter randomized trial for the stroke prevention in atrial fibrillation study
164. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin
165. Warfarin versus aspirin for prevention of thromembolic in atrial fibrillation
166. The natural history of sick sinus syndrome
167. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction
168. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
169. Effect of enalapril on survival in patients with reduced left vetricular ejection fractions and congestive heart failure
170. Determinants of the ventricular rate during atrial fibrillation
171. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy
172. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
173. Predictors of outcome after radiofrequency catheter ablation of the atrioventricular node for atrial fibrillation and congestive heart failure
174. Echocardiographic predictors of nonrheumatic atrial fibrillation
175. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs
176. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
177. Anticoagulation for cardioversion of atrial fibrillation
178. Atrioverter: An implantable device for the treatment of atrial fibrillation
179. Atrial fibrillation begets atrial fibrillation
180. Electrophysiological testing and nonsustained ventricular tachycardia
181. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation
182. Atrial fibrillation as an independent risk factor for stroke: The Framingham study
183. Impact of atrial fibrillation on mortality, stroke, and medical costs